证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2026-001 问 2：公司目前的研发思路以及在研品种的进展情况？ 答：公司立足生物制药领域，坚持创新引领公司发展的 策略，内部挖掘研发潜力，外部对接先进技术，积极与国内 外知名学者、专家合作，推动产学研联动和技术合作等工作， 形成"自主创新+外部引进"的研发模式。目前公司在研产 品的临床试验正在积极推进中，其中"HuA21 注射液"是公 司自主研发的 HER2 靶点的一款新药，与曲妥珠单抗联用可 协同增加肿瘤抑制效果，前期探索性研究阶段性数据呈现出 较好的安全性和疗效，已顺利完成 Ib/II 期临床研究的受试 者入组，将根据中期分析结果计划开展 III 期临床研究，目 前 III 期临床试验方案讨论会已经召开；"AK2024 注射液" 是公司开发的针对 HER2 靶点的创新药物，目前正在开展 I 期临床试验，临床前研究表明，"AK2024 注射液"可抑制 HER2 阳性肿瘤细胞的增殖，在增强曲妥珠单抗对肿瘤生长的 抑制作用方面，其协同效应明显优于帕妥珠单抗；"HK010 注射液"是公司开发的"PD ...

Core Insights - Anke Bio's stock price reached a peak of 10.50 yuan, with an increase of 2.1% [1] - The company's targeted therapy drug, Ansatin (Trastuzumab), is primarily used for HER2-positive breast cancer and gastric cancer, marking its first product in the oncology targeted drug sector [1] - Anke Bio anticipates sales revenue from Trastuzumab to exceed 100 million yuan in 2024, with a significant year-on-year growth expected in 2025 [1][3] Financial Performance - Anke Bio reported total revenue of 1.292 billion yuan for the first half of 2025, remaining stable compared to 1.299 billion yuan in 2024 [3] - The company's gross profit was approximately 988 million yuan, resulting in a gross margin of 76.45% [3] - Net profit attributable to the parent company was 367 million yuan, reflecting a year-on-year decline of 11.92%, attributed to investments in multiple new drug research pipelines [3] R&D Progress - Anke Bio has several clinical projects in various stages, including HuA21 injection in phase I, PA3-17 injection in phase I, and others in phase II and III [4][6] - The company is actively developing 13 new clinical drugs, indicating a robust pipeline for future growth [6]